Synonym
DESOGESTREL; Cerazette; Desogen; Desogestrelum; Org-2969; Org2969; Org 2969;
IUPAC/Chemical Name
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
InChi Key
RPLCPCMSCLEKRS-BPIQYHPVSA-N
InChi Code
InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
SMILES Code
O[C@@]([C@@]1(CC)C2)(C#C)CC[C@@]1([H])[C@]3([H])CCC4=CCCC[C@]4([H])[C@@]3([H])C2=C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
310.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Stone SC. Desogestrel. Clin Obstet Gynecol. 1995 Dec;38(4):821-8. doi: 10.1097/00003081-199538040-00017. PMID: 8616978.
2: Phizackerley D, Girling J, Cave JA. Desogestrel POM to P: for the few not the many? Drug Ther Bull. 2021 Oct;59(10):146. doi: 10.1136/dtb.2021.000049. Epub 2021 Aug 23. PMID: 34426511.
3: Collins D. Selectivity information on desogestrel. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 2):1010-6. doi: 10.1016/0002-9378(93)90330-l. PMID: 8447353.
4: Shoupe D. Effects of desogestrel on carbohydrate metabolism. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 2):1041-7. doi: 10.1016/0002-9378(93)90335-g. PMID: 8447358.
5: Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother. 1995 Jul-Aug;29(7-8):736-42. doi: 10.1177/106002809502907-817. PMID: 8520092.
6: Faculty of Family Planning & Reproductive Health Care, Clinical Effectiveness Unit. Desogestrel-only pill (Cerazette). J Fam Plann Reprod Health Care. 2003 Jul;29(3):162-4. doi: 10.1783/147118903101197593. PMID: 12885316.
7: Scala C, Leone Roberti Maggiore U, Remorgida V, Venturini PL, Ferrero S. Drug safety evaluation of desogestrel. Expert Opin Drug Saf. 2013 May;12(3):433-44. doi: 10.1517/14740338.2013.788147. Epub 2013 Apr 8. PMID: 23560561.
8: Burton RC, Williams CE. Double-Dose Desogestrel: Is it Effective in Adolescent Menstrual Dysfunction? J Pediatr Adolesc Gynecol. 2021 Oct;34(5):662-665. doi: 10.1016/j.jpag.2021.04.015. Epub 2021 May 11. PMID: 33989805.
9: Güven AG, Jaferi L, Pehlivantürk-Kızılkan M. "Double-dose desogestrel: Is it effective in adolescent menstrual dysfunction?". J Pediatr Adolesc Gynecol. 2022 Aug;35(4):518. doi: 10.1016/j.jpag.2022.03.001. Epub 2022 Mar 23. PMID: 35337988.
10: Burkman RT. Lipid metabolism effects with desogestrel-containing oral contraceptives. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 2):1033-40. doi: 10.1016/0002-9378(93)90334-f. PMID: 8447357.
11: Archer DF. Clinical and metabolic features of desogestrel: a new oral contraceptive preparation. Am J Obstet Gynecol. 1994 May;170(5 Pt 2):1550-5. doi: 10.1016/s0002-9378(94)05018-0. PMID: 8178905.
12: Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):1-10. doi: 10.1517/17425255.2013.844229. Epub 2013 Oct 9. PMID: 24102478.
13: Ciebiera M, Zgliczyńska M, Zgliczyński S, Sierant A, Laganà AS, Alonso Pacheco L, Carugno J, Vitale SG. Oral Desogestrel as Endometrial Preparation before Operative Hysteroscopy: A Systematic Review. Gynecol Obstet Invest. 2021;86(3):209-217. doi: 10.1159/000514584. Epub 2021 May 5. PMID: 33951627.
14: Lauritzen C. Comments on desogestrel and gestoden (3rd generation progestogens) and the incidence of thromboembolism. Horm Metab Res. 1996 May;28(5):245-7. doi: 10.1055/s-2007-979175. PMID: 8738115.
15: Stubblefield PG. The effects on hemostasis of oral contraceptives containing desogestrel. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 2):1047-52. doi: 10.1016/0002-9378(93)90336-h. PMID: 8447359.
16: Stone S. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol. Int J Fertil Menopausal Stud. 1993;38 Suppl 3:117-21. PMID: 8260969.
17: Corson SL. Contraceptive efficacy of a monophasic oral contraceptive containing desogestrel. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 2):1017-20. doi: 10.1016/0002-9378(93)90331-c. PMID: 8447354.
18: Moray KV, Chaurasia H, Sachin O, Joshi B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health. 2021 Jan 6;18(1):4. doi: 10.1186/s12978-020-01054-y. PMID: 33407632; PMCID: PMC7788930.
19: Joubert F, Perrin-Terrin AS, Verkaeren E, Cardot P, Fiamma MN, Frugière A, Rivals I, Similowski T, Straus C, Bodineau L. Desogestrel enhances ventilation in ondine patients: Animal data involving serotoninergic systems. Neuropharmacology. 2016 Aug;107:339-350. doi: 10.1016/j.neuropharm.2016.03.041. Epub 2016 Apr 1. PMID: 27040794.
20: Burton RC, Williams CE. "Double-dose desogestrel: Is it effective in adolescent menstrual dysfunction?" - Response to Güven et al. J Pediatr Adolesc Gynecol. 2022 Aug;35(4):519. doi: 10.1016/j.jpag.2022.03.002. Epub 2022 Mar 23. PMID: 35337987.
